Category Archives: Br J Dermatol

Related Articles
Interpretability in atopic dermatitis: all about the anchor.
Br J Dermatol. 2018 Apr;178(4):832-833
Authors: Oosterhaven JAF
PMID: 29668100 [PubMed – in process]

Continue reading →

Continuous usage of a hair dye product containing 2-methoxymethyl-p-phenylenediamine by hair dye allergic individuals.

Br J Dermatol. 2016 Jan 8;

Authors: Kock M, Coenraads PJ, Blömeke B, Goebel C

Abstract
BACKGROUND: Despite a positive patch test reaction to p-phenylenediamine (PPD) and/or toluene-2,5-diamine (PTD) many people attempt to continue dyeing their hair with products containing PPD or its derivatives.
OBJECTIVES: Investigation of elicitation reactions among PPD/PTD allergic individuals to hair dye products containing the less-sensitizing PPD-derivative 2-methoxymethyl-p-phenylenediamine (ME-PPD).
METHODS: Elicitation reactions were studied in 43 PPD/PTD allergic individuals by a 45-min pre-test with a ME-PPD containing hair dye on their forearm and upon negative result followed by exposure to subsequent hair colour treatment(s).
RESULTS: 38/43 PPD/PTD allergic individuals did not develop an elicitation reaction during the pre-test with ME-PPD containing hair dye products and were eligible for subsequent hair colour treatments. Of these 38 PPD/PTD allergic individuals 29 tolerated subsequent hair dyeing with ME-PPD containing hair dye products while 9 showed mild to moderate allergic reactions upon the first hair colour treatment.
CONCLUSIONS: Hair dye products with the less sensitizing ME-PPD were tolerated by 29/43 (67%) PPD/PTD allergic individuals throughout continued hair dyeing with an average of 9 treatments per year. Five individuals reacted upon pre-testing while only mild to moderate skin reactions occurred upon hair dyeing in 9 individuals who were not identified by the pre-test. To our knowledge this is the first study among PPD/PTD allergic individuals indicating that a negative 45 min pre-testing with a hair dye product helps to avoid severe allergic reactions. This article is protected by copyright. All rights reserved.

PMID: 26749506 [PubMed – as supplied by publisher]

Continue reading →

Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum.

Br J Dermatol. 2015 Dec 7;

Authors: Blok JL, Li K, Brodmerkel C, Horvátovich P, Jonkman MF, Horváth B

Abstract
BACKGROUND: Treatment of hidradenitis suppurativa (HS) is difficult and the search for effective therapies continues.
OBJECTIVES: 1.To evaluate the efficacy of ustekinumab. 2.To discover a potential biomarker.
METHODS: Seventeen patients were included in this open label study and treated with 45 to 90 mg ustekinumab at weeks 0, 4, 16 and 28. Proteomic technology and enzyme-linked assay analysis (ELISA) was applied on serum.
RESULTS: Twelve patients completed the protocol. Moderate to marked improvement of the modified Sartorius Score was achieved in 82% of patients at week 40 and the hidradenitis suppurativa clinical response (HiSCR-50) in 47%. At baseline, a significant difference was observed in the expression of 54 serum proteins between patients and healthy controls. Involved pathways were related to inflammation, immune cell signaling, and tissue morphology/development. Good responders had milder disease and lower expression of leukotriene A4-hydrolase (LTA4H). IL-2R, TNF-α, IL17A and IL-17F were not elevated and did not change during treatment.
CONCLUSIONS: The majority of patients improved with ustekinumab. Although no biomarker was discovered, low LTA4H concentrations with mild disease severity may be predictive for the effectiveness of ustekinumab. This article is protected by copyright. All rights reserved.

PMID: 26641739 [PubMed – as supplied by publisher]

Continue reading →

Direct and indirect immunofluorescence staining patterns in the diagnosis of paraneoplastic pemphigus.
Br J Dermatol. 2015 Nov 11;
Authors: Poot AM, Siland J, Jonkman MF, Pas HH, Diercks GF
Abstract
P… Continue reading →

Contact dermatitis in the construction industry: the role of filaggrin loss-of-function mutations.
Br J Dermatol. 2015 Oct 9;
Authors: Timmerman JG, Heederik D, Spee T, van Rooy FG, Krop EJ, Koppelman GH, Rustemeyer … Continue reading →

Prevalence of fragrance contact allergy in the general population of five European countries – a cross-sectional study.

Br J Dermatol. 2015 Sep 2;

Authors: Diepgen TL, Ofenloch R, Bruze M, Cazzaniga S, Coenraads PJ, Elsner P, Goncalo M, Svensson Å, Naldi L

Abstract
BACKGROUND: Contact allergy to fragrances is mostly assessed in clinical populations of patients. Studies in the general population are scarce and vary in their methodology across countries.
OBJECTIVES: To determine the prevalence of fragrance contact allergy in the European general population and to assess the clinical relevance of positive patch test reactions to different fragrances.
METHODS: In five European countries (Germany, Italy, The Netherlands, Portugal and Sweden) a random sample from the general population aged 18 to 74 years was drawn. In total 12,377 subjects were interviewed in this cross-sectional study and a random sample (n=3,119) was patch tested using True test and Finn chamber technique. Patch test procedures were harmonized by a mandatory training in advance of and a monitoring during the study.
RESULTS: The highest prevalence for contact allergy of 2.6% (95% CI 2.1-3.2) was found for FM I in petrolatum with a high content of atranol and chloratranol, and 1.9% (95% CI 1.5-2.4) for FM II in petrolatum. The conservatively estimated prevalence of fragrance contact allergy (defined by the existence of a positive patch test to Fragrance Mix I (FM I) or Fragrance Mix II (FM II) or any of the individual materials in either FM I or FM II or Myroxylon pereirae or sesquiterpene lactones or 3 and 4-hydroxyisohexyl 3-cyclohexene carboxaldehyde) that show clinical relevance, defined conservatively as lifetime avoidance of scented products and an itchy skin rash lasting more than 3 days in a lifetime, was 1.9% (95% CI 1.5-2.5). If we use the reported lifetime prevalence of any contact dermatitis instead of the lifetime prevalence of any itchy skin rash, the prevalence is 0.8% (95% CI 0.5-1.2).The prevalence rates of contact allergy to fragrances in females are about two times higher than in males.
CONCLUSIONS: The study helps identifying targets for prevention of fragrance allergy. This article is protected by copyright. All rights reserved.

PMID: 26332456 [PubMed – as supplied by publisher]

Continue reading →

Related Articles

Laboratory diagnosis of paraneoplastic pemphigus.

Br J Dermatol. 2013 Nov;169(5):1016-24

Authors: Poot AM, Diercks GF, Kramer D, Schepens I, Klunder G, Hashimoto T, Borradori L, Jonkman MF, Pas HH

Abstract
BACKGROUND: Paraneoplastic pemphigus (PNP) is a multiorgan disease characterized by antibodies against plakins, desmogleins and the α2-macroglobulin-like-1 (A2ML1) protein, in association with an underlying neoplasm. Accurate diagnosis relies on the demonstration of these autoantibodies in serum.
OBJECTIVES: To evaluate the value of different laboratory techniques in the serological diagnosis of PNP.
METHODS: We performed immunoblotting, envoplakin (EP) enzyme-linked immunosorbent assay (ELISA), indirect immunofluorescence (IIF) on rat bladder, radioactive immunoprecipitation and a nonradioactive combined immunoprecipitation-immunoblot assay. Additional assays included BP180 ELISA and BP230 ELISA. We included the sera of 19 patients with PNP and 40 control subjects.
RESULTS: The sensitivities were 63% for anti-EP ELISA, 74% for rat bladder IIF, 89% for immunoblotting, 95% for radioactive immunoprecipitation and 100% for nonradioactive immunoprecipitation. Specificities ranged from 86% to 100%. The BP180 and BP230 ELISAs had low sensitivity and specificity for PNP. The combination of rat bladder IIF and immunoblot showed 100% sensitivity and specificity. The analysis of sequential PNP sera showed that antibody titres may decrease over time, possibly resulting in negative outcomes for EP ELISA and rat bladder IIF studies.
CONCLUSIONS: The detection of autoantibodies against EP and periplakin, or A2ML1 by immunoprecipitation is most sensitive for PNP. The combination of rat bladder IIF and immunoblotting is equally sensitive and highly specific, and represents an alternative valuable and relatively easy approach for the serological diagnosis of PNP.

PMID: 23796242 [PubMed – indexed for MEDLINE]

Continue reading →

Related Articles
Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study.
Br J Dermatol. 2013 Nov;169(5):1071-80
Author… Continue reading →